secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medicus Pharma Ltd. (MDCX)
CIK:        0001997296
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001062993-25-005105
Event type: other
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medicus Pharma closes $4.2M Reg A offering of 1.49M units at $2.80/unit
-----------------------------------------------------------------------

- Gross proceeds $4,172,000 from 1,490,000 units (one share + one warrant) priced at $2.80/unit; closed March 10, 2025.
- Warrants exercisable at $2.80/share for 5 years from issuance; not listed on any exchange.
- Net proceeds to fund Phase 2 proof-of-concept trial for basal cell carcinoma using doxorubicin microarray needle patch.
- Maxim Group LLC lead placement agent; customary 7.5% cash fee plus expense reimbursement.
- Offering qualified under Tier II Regulation A on March 6, 2025; subscription agreement with a single investor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325005105/0001062993-25-005105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325005105/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-25-005105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer